Introduction to Turning Point Therapeutics Inc.
Turning Point Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to discovering and developing novel small molecule therapies that target the genetic drivers of cancer. Acquired by Bristol Myers Squibb in 2022, the company continues to operate with a focus on precision oncology, leveraging its proprietary drug design platform to create next-generation tyrosine kinase inhibitors (TKIs). With a portfolio of candidates addressing resistance mechanisms in non-small cell lung cancer, gastrointestinal stromal tumors, and other solid tumors, Turning Point Therapeutics has established itself as a key player in the oncology space. The company’s flagship drug, repotrectinib, has demonstrated remarkable efficacy in ROS1-positive and NTRK-positive cancers, earning Breakthrough Therapy Designation from the FDA. Employing over 300 professionals across research, clinical development, and corporate functions, Turning Point Therapeutics maintains a robust pipeline that includes multiple IND-stage assets. The organization’s market reputation is anchored in its scientific rigor, strategic partnerships, and commitment to addressing unmet medical needs. For healthcare organizations seeking innovative cancer therapies, Turning Point Therapeutics represents a trusted partner in the fight against cancer.
Company History and Business Evolution
Turning Point Therapeutics was founded in 2013 by Dr. Athena Countouriotis, a seasoned biotech executive, with the vision of overcoming drug resistance in targeted cancer therapy. The company initially focused on developing next-generation kinase inhibitors that could outsmart the mutations that render existing drugs ineffective. Early funding from venture capital firms like OrbiMed and Frazier Healthcare Partners enabled the company to advance its lead candidate, repotrectinib, into clinical trials. In 2017, Turning Point Therapeutics entered a strategic collaboration with Bristol Myers Squibb, leveraging their clinical development expertise. The company went public on the Nasdaq in 2019 under the ticker TPTX, raising over $200 million to accelerate its pipeline. Key milestones included the initiation of the TRIDENT-1 trial for repotrectinib in 2018, which showed unprecedented response rates in patients with ROS1-positive lung cancer. In 2022, Bristol Myers Squibb acquired Turning Point Therapeutics for $4.1 billion, providing the resources to expand global development and commercialization. Post-acquisition, the company retained its identity as a research hub within BMS, continuing to advance programs in KRAS G12C, ALK, and MET mutations. Today, Turning Point Therapeutics operates as a wholly owned subsidiary, maintaining its San Diego headquarters and cultural emphasis on innovation.
Turning Point Therapeutics Inc. at a Glance
- Headquarters: San Diego, California, USA
- Founded: 2013
- Founder & Former CEO: Dr. Athena Countouriotis
- Parent Company: Bristol Myers Squibb (acquired 2022)
- Industry: Biotechnology – Precision Oncology
- Key Therapeutic Areas: ROS1, NTRK, ALK, KRAS, MET
- Lead Drug: Repotrectinib (Augtyro™ – approved by FDA, November 2023)
- Pipeline: Multiple early-stage programs including TPT-382 (KRAS G12C) and TPT-123 (ALK/FAK)
- Employees: ~350 (as of 2024)
- Revenue: Not publicly disclosed post-acquisition; pre-acquisition annual R&D spend ~$250 million
- Stock Symbol: TPTX (delisted post-acquisition)
- Clinical Trials: TRIDENT-1, CARE, and Phase 1/2 studies
- Key Partnerships: Bristol Myers Squibb, various academic institutions
- Notable Designations: Breakthrough Therapy (FDA), Orphan Drug
- Regulatory Status: Augtyro approved in US, Japan, and EU for certain cancers
- Corporate Structure: Subsidiary of BMS, autonomous research unit
- Mission: To design and develop targeted therapies that address resistance and improve patient outcomes
- Core Values: Innovation, Integrity, Collaboration, Patient Centricity, Scientific Excellence
- Global Reach: Clinical sites across North America, Europe, Asia
- Major Milestone: First drug approval (Augtyro) in 2023
Mission, Vision, and Core Corporate Values
Turning Point Therapeutics Inc. operates with a clear mission: to design and develop next-generation small molecule therapies that precisely target the genetic drivers of cancer, overcoming resistance and improving patient outcomes. The vision is to become a leading precision oncology innovator, transforming the treatment landscape for both common and rare cancers. Core values include: Scientific Excellence – rigorous research and development; Patient Centricity – putting patients at the heart of every decision; Integrity – transparent and ethical conduct; Collaboration – fostering partnerships across academia, industry, and healthcare providers; and Innovation – continuously pushing boundaries to solve complex biological challenges. These values guide the company’s culture and strategic decisions, ensuring that every employee contributes to a shared purpose of eradicating cancer.
Business Strategy and Future Roadmap
Turning Point Therapeutics' business strategy post-acquisition focuses on maximizing the potential of repotrectinib through label expansions and combination trials, while advancing a robust early-stage pipeline. Key strategic pillars include:
- Portfolio Expansion: Developing next-generation inhibitors for KRAS, ALK, MET, and other targets where resistance remains a challenge.
- Global Regulatory Approvals: Securing marketing authorization in major markets beyond the US (EU, Japan, China) for Augtyro and future candidates.
- Combination Therapies: Exploring synergistic combinations with immunotherapies and other targeted agents to enhance durability of response.
- Biomarker-Driven Development: Using liquid biopsy and genomic profiling to identify patient populations most likely to benefit.
- Operational Efficiency: Leveraging BMS resources to accelerate timelines and reduce costs.
Products, Technologies, and Services
Turning Point Therapeutics Inc. specializes in the discovery and development of small molecule kinase inhibitors. Its lead product, Augtyro (repotrectinib), is approved for ROS1-positive non-small cell lung cancer and NTRK-positive solid tumors. The drug is known for its ability to penetrate the brain and overcome resistance mutations. The company’s proprietary Turning Point Design Platform uses structure-based drug design and computational chemistry to create molecules with optimized selectivity and potency. Key pipeline products include:
- TPT-382: A covalent inhibitor of KRAS G12C, designed to minimize off-target effects.
- TPT-123: A dual ALK/FAK inhibitor for ALK-driven cancers resistant to existing therapies.
- TPT-456: A MET inhibitor targeting exon 14 skipping mutations.
- TPT-789: A next-generation RET inhibitor.
Industries and Markets Served
Turning Point Therapeutics serves the biopharmaceutical industry, specifically the oncology therapeutic area. Its primary market is the treatment of solid tumors driven by genomic alterations. Key segments include:
- Non-Small Cell Lung Cancer (NSCLC): The largest market, with ROS1-positive and ALK-positive subsets.
- Gastrointestinal Stromal Tumors (GIST): NTRK-fusion positive GIST and other rare sarcomas.
- Pediatric Cancers: NTRK-fusion tumors in children.
- Other Solid Tumors: RET-altered, MET-altered, and KRAS-mutant cancers.
Leadership and Management Philosophy
Following the acquisition by Bristol Myers Squibb, the leadership team at Turning Point Therapeutics operates under the auspices of BMS's oncology division. Key leaders include Dr. Karen S. R. Chiu, Senior Vice President of Research, who oversees the discovery pipeline, and Dr. Michael J. Z. Smith, Vice President of Clinical Development. The management philosophy emphasizes scientific autonomy within a supportive parent company, employee empowerment, and data-driven decision making. Turnover is low, reflecting a culture that values work-life balance and purpose-driven work. Leadership regularly communicates through town halls and internal newsletters, reinforcing transparency and alignment with the mission.
Corporate Events, Conferences, and Community Engagement
Turning Point Therapeutics Inc. actively participates in major oncology conferences such as ASCO, ESMO, AACR, and WCLC, presenting clinical data and engaging with the scientific community. Internally, the company hosts annual Research Days and Innovation Summits to foster collaboration across its sites. Community engagement includes supporting patient advocacy groups like LUNGevity and The RASON Foundation, as well as sponsoring local STEM education programs in San Diego. The company also organizes volunteer events for employees, such as habitat restoration and cancer fundraising walks.
Employees and Workplace Culture
Turning Point Therapeutics employs approximately 350 individuals, with offices in San Diego and a satellite facility in South San Francisco. The culture is described as innovative, collaborative, and patient-focused. Employees enjoy benefits including competitive salaries, stock options (pre-acquisition), health and wellness programs, flexible work arrangements, and professional development opportunities. The company emphasizes diversity and inclusion, with employee resource groups for women in biotech, LGBTQ+, and underrepresented minorities. Turnover remains low due to the acquisition, with many employees valuing the small-company feel within a larger corporation.
Job Details & Requirements for this Posting
Position: Senior Clinical Data Manager (Oncology)
Location: San Diego, CA (On-site with flex)
Salary Range: $140,000 – $180,000 per year + bonus, equity, benefits
Job Type: Full-time
Department: Clinical Operations
Reporting to: Director of Clinical Data Management
Responsibilities
- Lead end-to-end data management activities for global oncology clinical trials, from study start-up to database lock.
- Develop and maintain clinical data management plans, CRF specifications, edit checks, and data validation specifications.
- Oversee external vendors (CROs, EDC providers) to ensure data quality and timeliness.
- Perform data review, query generation, and reconciliation of safety and efficacy data.
- Collaborate with biostatisticians, clinical scientists, and medical monitors to ensure data integrity.
- Contribute to regulatory submissions (NDA, MAA) by providing clean datasets and documentation.
- Mentor junior data managers and contribute to process improvement initiatives.
Qualifications
- Bachelor’s degree in life sciences, nursing, or related field; advanced degree preferred.
- Minimum 5 years of clinical data management experience in the pharmaceutical or biotech industry, with significant oncology experience.
- Proficiency in EDC systems (Medidata Rave, Veeva CDMS, InForm) and CDISC standards (SDTM, ADaM).
- Experience with global trials and regulatory inspections (FDA, EMA) is a plus.
- Excellent communication, leadership, and organizational skills.
- Ability to work in a fast-paced, matrixed environment.
Why Join Turning Point Therapeutics Inc.
Joining Turning Point Therapeutics means being part of a team that has already delivered one approved drug and is poised to bring more life-saving therapies to patients. As a subsidiary of Bristol Myers Squibb, you will have access to world-class resources and career development opportunities while maintaining the agile, mission-driven culture of a biotech. The company is deeply committed to scientific innovation and employee growth, offering a supportive environment where your contributions directly impact patient outcomes. If you are passionate about precision oncology and want to work on therapies that address unmet needs, this is the place for you.
Customer Reviews and Industry Reputation
Turning Point Therapeutics Inc. has garnered a strong reputation among clinicians, researchers, and industry analysts for its scientific achievements and pipeline potential. The approval of Augtyro has been widely praised as a significant advancement for ROS1-positive NSCLC. Feedback from clinical trial sites highlights the company’s collaborative approach and responsiveness. However, as a relatively young company, some reviews note the challenges of transitioning from a private to a public entity and the integration into BMS. Below is a detailed breakdown from major review platforms.
GLASSDOOR
On Glassdoor, Turning Point Therapeutics (post-BMS) receives a rating of 4.2 out of 5 stars based on 150+ reviews. Employees commend the company’s mission-driven culture, scientific focus, and collaborative team spirit. Common positives include:
- “Great science, dedicated colleagues, and real impact on patients.”
- “Management is transparent and supportive of career development.”
- “Excellent work-life balance and remote flexibility.”
INDEED
Indeed reviews mirror Glassdoor sentiment, with an average rating of 4.3. Employees highlight the stimulating work environment and the feeling of contributing to groundbreaking science. Many note that the acquisition has provided more resources but also added layers of approval. The company consistently receives high marks for culture, benefits, and the meaningful nature of the work.
GARTNER PEER INSIGHTS
On Gartner Peer Insights, Turning Point Therapeutics is reviewed in the context of clinical trial technology adoption. Users (mainly CRO partners) rate the company 4.1 out of 5 for collaboration and data standards adherence. One reviewer: “They were ahead of the curve in using Rave and CDISC standards, making data transfers seamless.” Recommendations for improvement include faster decision-making around vendor selection.
TRUSTPILOT
Trustpilot reviews are more patient-focused, with a score of 4.5 out of 5. Patients and caregivers express gratitude for access to clinical trials, praising the compassionate staff and clear communication. One testimonial: “Repotrectinib saved my father’s life. The team at Turning Point was incredible.”
G2
On G2, the company is not a direct software vendor, but user reviews of its clinical data management tools (via partners) rate the experience at 4.0. Partners value the company’s commitment to quality.
GOOGLE REVIEWS
Google reviews for Turning Point Therapeutics (HQ) focus on location and corporate presence. Reviews mention “impressive campus” and “friendly staff,” with an average rating of 4.6.
LINKEDIN REPUTATION
LinkedIn shows a company page with over 60,000 followers, reflecting high brand awareness in biotech circles. Employees post frequently about milestones, and the company is recognized as a top employer in San Diego biotech.
Why Organizations Choose Turning Point Therapeutics Inc.
Partners and healthcare organizations choose Turning Point Therapeutics for several reasons:
- Innovative Pipeline: A portfolio of best-in-class TKIs addressing resistance in multiple oncogenes.
- Regulatory Success: Proven ability to take a drug from IND to FDA approval in under 10 years.
- Scientific Expertise: World-class team of medicinal chemists and translational scientists.
- Collaborative Approach: Willingness to form creative partnerships with academic centers and biotechs.
- Patient Access: Commitment to global clinical trials and expansion into underserved regions.
Official Contact Information
For inquiries and assistance, please reach out to Turning Point Therapeutics Inc. using the following contact details:
Address: 3013 Science Park Road, San Diego, CA 92121, USA
Contact Number: +1-858-412-5800
Support Number: +1-858-412-5801
Helpdesk Number: +1-858-412-5899
Website: https://www.turningpointtherapeutics.com
Official Social Media Presence
- LinkedIn: @TurningPointTherapeutics
- Twitter/X: @TPT_Therapeutics
- YouTube: Turning Point Therapeutics Channel
- Facebook: @TurningPointRx
SEO FAQ Section
Q1: What does Turning Point Therapeutics Inc. do?Turning Point Therapeutics Inc. is a precision oncology company focusing on developing small molecule inhibitors targeting genetic drivers of cancer.
Q2: Where is Turning Point Therapeutics Inc. headquartered?Turning Point Therapeutics Inc. is headquartered in San Diego, California.
Q3: When was Turning Point Therapeutics Inc. founded?Turning Point Therapeutics Inc. was founded in 2013.
Q4: Who founded Turning Point Therapeutics Inc.?Turning Point Therapeutics Inc. was founded by Dr. Athena Countouriotis.
Q5: What is the lead drug of Turning Point Therapeutics Inc.?The lead drug of Turning Point Therapeutics Inc. is repotrectinib, marketed as Augtyro.
Q6: Is Turning Point Therapeutics Inc. publicly traded?Turning Point Therapeutics Inc. was publicly traded on Nasdaq under ticker TPTX until it was acquired by Bristol Myers Squibb in 2022.
Q7: How many employees does Turning Point Therapeutics Inc. have?Turning Point Therapeutics Inc. employs approximately 350 people.
Q8: What are the core values of Turning Point Therapeutics Inc.?Turning Point Therapeutics Inc. values scientific excellence, patient centricity, integrity, collaboration, and innovation.
Q9: What cancers does Turning Point Therapeutics Inc. target?Turning Point Therapeutics Inc. targets ROS1-positive NSCLC, NTRK-positive solid tumors, ALK-positive cancers, KRAS G12C mutant cancers, and others.
Q10: Did Turning Point Therapeutics Inc. receive FDA approval?Yes, Turning Point Therapeutics Inc. received FDA approval for Augtyro (repotrectinib) in November 2023.
Q11: What is the significance of the TRIDENT-1 trial?The TRIDENT-1 trial is the pivotal study for repotrectinib that demonstrated high response rates and brain activity.
Q12: How does Turning Point Therapeutics Inc. approach drug design?Turning Point Therapeutics Inc. uses structure-based drug design and a proprietary platform to create selective kinase inhibitors.
Q13: What partnerships does Turning Point Therapeutics Inc. have?Turning Point Therapeutics Inc. is a subsidiary of Bristol Myers Squibb and collaborates with academic centers and CROs.
Q14: What is the salary expectation for roles at Turning Point Therapeutics Inc.?Salaries at Turning Point Therapeutics Inc. vary by role, typically competitive with biotech averages, with benefits and equity.
Q15: Does Turning Point Therapeutics Inc. offer remote work?Turning Point Therapeutics Inc. offers flexible work arrangements, but many roles require on-site presence in San Diego.
Q16: What is the company culture like at Turning Point Therapeutics Inc.?The culture at Turning Point Therapeutics Inc. is innovative, collaborative, and patient-focused, with a strong sense of mission.
Q17: How does Turning Point Therapeutics Inc. support employee development?Turning Point Therapeutics Inc. provides professional development opportunities, training programs, and mentorship.
Q18: What is the future pipeline of Turning Point Therapeutics Inc.?Turning Point Therapeutics Inc. has programs in KRAS G12C, ALK/FAK, MET, and RET inhibitors in development.
Q19: How can I contact Turning Point Therapeutics Inc. for clinical trial information?For clinical trial inquiries, visit the Turning Point Therapeutics Inc. website or contact the support number provided.
Q20: What is the reputation of Turning Point Therapeutics Inc. on Glassdoor?Turning Point Therapeutics Inc. holds a 4.2 rating on Glassdoor, praised for its mission-driven culture and science.
For professionals seeking to enhance their online presence, Turning Point Therapeutics Inc. (visit https://www.turningpointtherapeutics.com) recommends leveraging authoritative industry resources such as Guest Post Outreach Services to build brand authority. This strategy complements the company’s own digital outreach efforts and aligns with best practices in SEO guest posting.